Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 10, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Transition Report | false | |
Entity File Number | 000-52985 | |
Entity Registrant Name | SANUWAVE Health, Inc. | |
Entity Central Index Key | 0001417663 | |
Entity Incorporation, State or Country Code | NV | |
Entity Tax Identification Number | 20-1176000 | |
Entity Address, Address Line One | 11495 Valley View Road | |
Entity Address, City or Town | Eden Prairie | |
Entity Address, State or Province | MN | |
Entity Address, Postal Zip Code | 55344 | |
City Area Code | 770 | |
Local Phone Number | 419-7525 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 548,737,651 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Cash | $ 1,112 | $ 619 |
Accounts receivable, net of allowance for doubtful accounts of $0.8 million, respectively | 2,403 | 2,415 |
Inventory | 1,413 | 1,040 |
Prepaid expenses and other current assets | 1,935 | 326 |
Total Current Assets | 6,863 | 4,400 |
Property, Equipment and Other, net | 673 | 1,118 |
Other Intangible Assets, net | 5,313 | 5,841 |
Goodwill | 7,260 | 7,260 |
Total Assets | 20,109 | 18,619 |
Current Liabilities: | ||
Senior secured promissory note payable, in default | 12,773 | 11,586 |
Convertible promissory notes payable, in default | 4,000 | 11,601 |
Convertible promissory notes, related parties, in default | 1,373 | 1,596 |
Convertible promissory notes payable | 9,174 | 0 |
Convertible promissory notes payable, related parties | 4,485 | 0 |
Advances on future cash receipts | 194 | 446 |
Accounts payable | 5,055 | 7,644 |
Accrued expenses | 4,100 | 4,394 |
Accrued employee compensation | 3,792 | 4,247 |
Due under factoring agreement | 1,510 | 1,737 |
Warrant liability | 1,196 | 9,614 |
Current portion of SBA loans | 0 | 158 |
Accrued interest | 3,988 | 2,521 |
Accrued interest, related parties | 546 | 289 |
Current portion of lease and contract liabilities | 249 | 316 |
Other | 30 | 114 |
Total Current Liabilities | 52,465 | 56,263 |
Non-current Liabilities | ||
SBA loans | 0 | 875 |
Lease liabilities | 263 | 118 |
Contract liabilities | 205 | 293 |
Deferred tax liability | 28 | 28 |
Total Non-current Liabilities | 496 | 1,314 |
Total Liabilities | 52,961 | 57,577 |
Commitments and Contingencies (Footnote 11) | ||
STOCKHOLDERS' DEFICIT | ||
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D no shares issued and outstanding at September 30, 2022 and December 31, 2021 | 0 | 0 |
Common Stock, par value $0.001, 800,000,000 shares authorized; 548,737,651 and 481,619,621 issued and outstanding at September 30, 2022 December 31, 2021, respectively | 549 | 482 |
Additional Paid-in Capital | 152,750 | 144,582 |
Accumulated Deficit | (186,084) | (183,949) |
Accumulated Other Comprehensive Loss | (67) | (73) |
Total Stockholders' Deficit | (32,852) | (38,958) |
Total Liabilities and Stockholders' Deficit | $ 20,109 | $ 18,619 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Accounts receivable, allowance for doubtful accounts | $ 0.8 | $ 0.8 |
STOCKHOLDERS' DEFICIT | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 800,000,000 | 800,000,000 |
Common stock, shares issued (in shares) | 548,737,651 | 481,619,621 |
Common stock, shares outstanding (in shares) | 548,737,651 | 481,619,621 |
Series A Convertible Preferred Stock [Member] | ||
STOCKHOLDERS' DEFICIT | ||
Preferred stock, shares authorized (in shares) | 6,175 | 6,175 |
Series B Convertible Preferred Stock [Member] | ||
STOCKHOLDERS' DEFICIT | ||
Preferred stock, shares authorized (in shares) | 293 | 293 |
Series C Convertible Preferred Stock [Member] | ||
STOCKHOLDERS' DEFICIT | ||
Preferred stock, shares authorized (in shares) | 90 | 90 |
Series D Convertible Preferred Stock [Member] | ||
STOCKHOLDERS' DEFICIT | ||
Preferred stock, shares authorized (in shares) | 8 | 8 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues: | ||||
Total Revenue | $ 4,166 | $ 3,725 | $ 11,242 | $ 8,750 |
Cost of Revenues | 606 | 1,555 | 2,590 | 3,658 |
Gross Margin | 3,560 | 2,170 | 8,652 | 5,092 |
Operating Expenses: | ||||
General and administrative | 3,404 | 2,864 | 8,482 | 8,909 |
Selling and marketing | 1,650 | 2,150 | 5,037 | 6,450 |
Research and development | 157 | 297 | 494 | 923 |
Gain on sale of property and equipment, net | 0 | 0 | (690) | 0 |
Depreciation and amortization | 189 | 194 | 575 | 585 |
Total Operating Expenses | 5,400 | 5,505 | 13,898 | 16,867 |
Operating Loss | (1,840) | (3,335) | (5,246) | (11,775) |
Other Income (Expense): | ||||
Interest expense | (3,301) | (1,781) | (9,203) | (4,340) |
Interest expense, related party | (439) | (55) | (551) | (150) |
Change in fair value of derivative liabilities | 5,252 | 1,555 | 16,597 | 1,599 |
Loss on issuance of debt | 0 | (1,088) | (3,434) | (3,572) |
Gain / (loss) Loss on extinguishment of debt | (86) | 460 | (297) | 460 |
Gain / (loss) on foreign currency exchange | 1 | (2) | (1) | 2 |
Other Income (Expense), net | 1,427 | (911) | 3,111 | (6,001) |
Net Loss before Income Taxes | (413) | (4,246) | (2,135) | (17,776) |
Provision for Income Taxes | 0 | 6 | 0 | 28 |
Net Loss | (413) | (4,252) | (2,135) | (17,804) |
Other Comprehensive Loss | ||||
Foreign currency translation adjustments | 0 | 0 | 0 | (12) |
Total Comprehensive Loss | $ (413) | $ (4,252) | $ (2,135) | $ (17,816) |
Loss per Share: | ||||
Basic (in dollars per share) | $ 0 | $ (0.01) | $ 0 | $ (0.03) |
Diluted (in dollars per share) | $ 0 | $ (0.01) | $ 0 | $ (0.03) |
Weighted average shares outstanding, basic and diluted | ||||
Basic (in shares) | 561,069,625 | 518,310,781 | 542,484,779 | 518,370,156 |
Diluted (in shares) | 561,069,625 | 518,310,781 | 542,484,779 | 518,370,156 |
Accessory and Parts Revenue [Member] | ||||
Revenues: | ||||
Total Revenue | $ 3,012 | $ 2,067 | $ 7,866 | $ 5,645 |
Product [Member] | ||||
Revenues: | ||||
Total Revenue | 902 | 1,299 | 2,408 | 2,066 |
Rental Income [Member] | ||||
Revenues: | ||||
Total Revenue | 247 | 333 | 935 | 864 |
License Fees and Other [Member] | ||||
Revenues: | ||||
Total Revenue | $ 5 | $ 26 | $ 33 | $ 175 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive Loss [Member] | Total |
Beginning balance at Dec. 31, 2020 | $ 0 | $ 471 | $ 142,563 | $ (156,690) | $ (62) | $ (13,718) |
Beginning balance (in shares) at Dec. 31, 2020 | 0 | 470,694,621 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Cashless warrant exercise | $ 0 | $ 11 | (11) | 0 | 0 | 0 |
Cashless warrant exercise (in shares) | 0 | 10,925,000 | ||||
Reclassification of warrant liability due to cashless warrant exercise | $ 0 | $ 0 | 2,030 | 0 | 0 | 2,030 |
Reclassification of warrant liability due to cashless warrant exercise (in shares) | 0 | 0 | ||||
Net loss | $ 0 | $ 0 | 0 | (17,804) | 0 | (17,804) |
Foreign currency translation adjustment | 0 | 0 | 0 | 0 | (12) | (12) |
Ending balance at Sep. 30, 2021 | $ 0 | $ 482 | 144,582 | (174,494) | (74) | (29,504) |
Ending balance (in shares) at Sep. 30, 2021 | 0 | 481,619,621 | ||||
Beginning balance at Jun. 30, 2021 | $ 0 | $ 482 | 144,582 | (170,242) | (74) | (25,252) |
Beginning balance (in shares) at Jun. 30, 2021 | 0 | 481,619,621 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net loss | $ 0 | $ 0 | 0 | (4,252) | 0 | (4,252) |
Ending balance at Sep. 30, 2021 | $ 0 | $ 482 | 144,582 | (174,494) | (74) | (29,504) |
Ending balance (in shares) at Sep. 30, 2021 | 0 | 481,619,621 | ||||
Beginning balance at Dec. 31, 2021 | $ 0 | $ 482 | 144,582 | (183,949) | (73) | (38,958) |
Beginning balance (in shares) at Dec. 31, 2021 | 0 | 481,619,621 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Cashless warrant exercise | $ 0 | $ 14 | 2,152 | 0 | 0 | 2,166 |
Cashless warrant exercise (in shares) | 14,000,000 | |||||
Warrant exercise | $ 0 | $ 1 | 99 | 0 | 0 | 100 |
Warrant exercise (in shares) | 0 | 909,091 | ||||
Shares issued in conjunction with Note Payable | $ 0 | $ 20 | 3,700 | 0 | 0 | 3,720 |
Shares issued in conjunction with Note Payable (in shares) | 0 | 20,666,993 | ||||
Shares issued for settlement of debt and warrants | $ 0 | $ 20 | 1,341 | 0 | 0 | 1,361 |
Shares issued for settlement of debt and warrants (in shares) | 0 | 19,444,446 | ||||
Shares issued for services | $ 12 | 876 | 0 | 0 | 888 | |
Shares issued for services (in shares) | 12,097,500 | |||||
Net loss | $ 0 | $ 0 | 0 | (2,135) | 0 | (2,135) |
Foreign currency translation adjustment | 0 | 0 | 0 | 0 | 6 | 6 |
Ending balance at Sep. 30, 2022 | $ 0 | $ 549 | 152,750 | (186,084) | (67) | (32,852) |
Ending balance (in shares) at Sep. 30, 2022 | 0 | 548,737,651 | ||||
Beginning balance at Jun. 30, 2022 | $ 0 | $ 529 | 151,409 | (185,671) | (67) | (33,800) |
Beginning balance (in shares) at Jun. 30, 2022 | 0 | 529,293,205 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Shares issued for settlement of debt and warrants | $ 0 | $ 20 | 1,341 | 1,361 | ||
Shares issued for settlement of debt and warrants (in shares) | 0 | 19,444,446 | ||||
Net loss | $ 0 | $ 0 | 0 | (413) | 0 | (413) |
Ending balance at Sep. 30, 2022 | $ 0 | $ 549 | $ 152,750 | $ (186,084) | $ (67) | $ (32,852) |
Ending balance (in shares) at Sep. 30, 2022 | 0 | 548,737,651 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash Flows - Operating Activities: | ||
Net loss | $ (2,135) | $ (17,804) |
Adjustments to reconcile net loss to net cash used by operating activities | ||
Depreciation and Amortization | 681 | 970 |
Bad debt expense | 62 | 307 |
Income tax expense | 0 | 28 |
Shares issued for services | 888 | 0 |
Loss (Gain) on extinguishment of debt | 297 | (460) |
Gain on sale of property and equipment, net | (690) | 0 |
Change in fair value of derivative liabilities | (16,597) | (1,599) |
Loss on issuance of debt | 3,434 | 3,572 |
Amortization of debt issuance costs and original issue discount | 2,998 | 1,418 |
Accrued interest | 1,618 | 929 |
Interest payable, related parties | 168 | 150 |
Changes in operating assets and liabilities | ||
Accounts receivable - trade | 69 | (345) |
Inventory | (373) | 1,430 |
Prepaid expenses and other assets | (1,437) | (355) |
Accounts payable | (1,863) | 2,656 |
Accrued expenses | 271 | 1,652 |
Accrued employee compensation | (473) | 885 |
Contract liabilities | (94) | 60 |
Net Cash Used in Operating Activities | (13,176) | (6,506) |
Cash Flows - Investing Activities | ||
Proceeds from sale of property and equipment | 1,022 | 0 |
Purchase of property and equipment | 0 | (441) |
Net Cash Flows Provided by (Used in) Investing Activities | 1,022 | (441) |
Cash Flows - Financing Activities | ||
Proceeds from senior promissory notes | 2,940 | 940 |
Proceeds from short term notes | 640 | 125 |
Proceeds from factoring, net | (227) | 1,244 |
Proceeds from SBA loan | 0 | 1,033 |
Proceeds from warrant exercises | 100 | 0 |
Proceeds from convertible promissory notes | 12,366 | 1,928 |
Payments of principal on finance leases | (174) | (143) |
Payments of principal on convertible promissory notes, related parties, convertible promissory notes and SBA loans | (2,981) | (237) |
Net Cash Flows Provided by Financing Activities | 12,664 | 4,890 |
Effect of Exchange Rates on Cash | (17) | (53) |
Net Change in Cash During Period | 493 | (2,110) |
Cash at Beginning of Period | 619 | 2,437 |
Cash at End of Period | 1,112 | 327 |
Supplemental Information: | ||
Cash paid for interest | 3,345 | 1,993 |
Non-cash Investing and Financing Activities: | ||
Reclassification of warrant liability due to cashless warrant exercise | 2,166 | 2,030 |
Settlement of debt and warrants with stock | 1,361 | 0 |
Warrants issued in conjunction with senior secured promissory note payable | 2,654 | 0 |
Common shares issued in conjunction with senior secured promissory note payable | 3,720 | 0 |
Embedded conversion option with issuances of convertible debt | 2,309 | 2,740 |
Working capital balances refinanced into Convertible notes payable | 2,273 | 0 |
Warrant issuance in conjunction with convertible debt | $ 1,463 | $ 758 |
Nature of the Business and Basi
Nature of the Business and Basis of Presentation | 9 Months Ended |
Sep. 30, 2022 | |
Nature of the Business and Basis of Presentation [Abstract] | |
Nature of the Business and Basis of Presentation | 1. Nature of the Business and Basis of Presentation SANUWAVE Health, Inc. and Subsidiaries (“SANUWAVE” or the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device used for treating diabetic foot ulcers. Through the Company’s acquisition, on August 6, 2020, of the UltraMIST® assets from Celularity, Inc. (“Celularity”), SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market. Basis of Presentation – The condensed consolidated balance sheet on December 31, 2021, has been derived from the audited consolidated financial statements at that date but does not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. These financial statements should be read in conjunction with the Company’s December 31, 2021, Annual Report on Form 10-K filed with the SEC on May 13, 2022 (the “2021 Annual Report”). |
Going Concern
Going Concern | 9 Months Ended |
Sep. 30, 2022 | |
Going Concern [Abstract] | |
Going Concern | 2. Going Concern Our recurring losses from operations, the events of default on the Company’s notes payable, and dependency upon future issuances of equity or other financing to fund ongoing operations have raised substantial doubt as to our ability to continue as a going concern for a period of at least twelve months from the filing of this Form 10-Q. We will be required to raise additional funds to finance our operations and remain a going concern; we may not be able to do so, and/or the terms of any financings may not be advantageous to us. The continuation of our business is dependent upon raising additional capital. We expect to devote substantial resources for the commercialization of the dermaPACE device and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources. Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. In addition, there can be no assurances that our plans to obtain additional capital will be successful on the terms or timeline we expect, or at all. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or, if available, obtain funds through financing transactions with unfavorable terms. The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Summary of Significant Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 3. Summary of Significant Accounting Policies Significant accounting policies followed by the Company are summarized below and should be read in conjunction with those described in Note 3 to the consolidated financial statements in our 2021 Annual Report. Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and the estimated fair value of financial instruments, including warrants and embedded conversion options. |
Loss per Share
Loss per Share | 9 Months Ended |
Sep. 30, 2022 | |
Loss per Share [Abstract] | |
Loss per Share | 4. Loss per Share The net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares outstanding for the three and nine months ended September 30, 2022, and 2021. In accordance with Accounting Standards codification (“ASC”) Topic 260-10-45-13, Earnings Per Share Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows (shares in thousands): Three Months Ended Nine Months Ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Weighted average shares outstanding Common shares 540,584 481,620 519,127 481,620 Common shares issuable assuming exercise of nominally priced warrants 20,486 36,691 23,358 36,751 Weighted average shares outstanding 561,070 518,311 542,485 518,370 Diluted net loss per share would be computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net loss per share. As a result of the net loss for the three and nine months ended September 30, 2022, and 2021, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. Anti-dilutive equity securities consist of the following for the nine months ended September 30, 2022, and 2021, respectively (in thousands): Nine Months Ended September 30, 2022 September 30, 2021 Common stock options 21,246 31,760 Common stock purchase warrants 984,799 159,858 Convertible notes payable 483,588 98,675 1,489,633 290,293 |
Accrued Expenses
Accrued Expenses | 9 Months Ended |
Sep. 30, 2022 | |
Accrued Expenses [Abstract] | |
Accrued Expenses | 5. Accrued Expenses Accrued expenses consist of the following on September and December (in s): 2022 2021 Registration penalties $ 1,593 $ 1,950 License fees 893 893 Board of director’s fees 663 507 Other 951 1,044 $ 4,100 $ 4,394 There was no activity in the warranty reserve during the months ended September |
Concentration of Credit Risk an
Concentration of Credit Risk and Limited Suppliers | 9 Months Ended |
Sep. 30, 2022 | |
Concentration of Credit Risk and Limited Suppliers [Abstract] | |
Concentration of Credit Risk and Limited Suppliers | 6. Concentration of Credit Risk and Limited Suppliers Major customers are defined as customers whose accounts receivable, or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable from major customers of the Company for the periods indicated were as follows: September 30, 2022 December 31, 2021 Accounts Receivable: Customer A 12 % 24 % Customer B 10 % 16 % The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The of purchases from major vendors of the Company that exceeded of total purchases for the and nine months ended September and were as follows: Three Months Ended Nine Months Ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Purchases: Vendor A 18 % 52 % 18 % 46 % Vendor B n/a n/a n/a 15 % |
Notes Payable
Notes Payable | 9 Months Ended |
Sep. 30, 2022 | |
Notes Payable [Abstract] | |
Notes Payable | 7. Notes Payable The following two tables summarize outstanding notes payable as of September 30, 2022, and December 31, 2021 (dollars in thousands): As of 09/30/2022 (dollars in thousands) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable In default 20.5 % n/a $ 18,000 $ (5,227 ) $ - $ 12,773 2021 Convertible promissory notes payable In default 17.0 % $ 0.0538 4,000 - - 4,000 Convertible promissory notes payable, related parties In default 14.0 % $ 0.10 1,373 - - 1,373 Convertible notes payable August 5, 2023 15.0 % $ 0.04 10,849 (2,966 ) 1,291 9,174 Convertible notes payable, related parties August 5, 2023 15.0 % $ 0.04 5,305 (1,451 ) 631 4,485 Advances on future cash receipts In default n/a n/a 296 (102 ) - 194 Total short-term debt as of September 30, 2022, including notes in default $ 39,823 $ (9,746 ) $ 1,922 $ 31,999 As of 12/31/2021 (dollars in thousands) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable In default 20.25 % n/a $ 15,000 $ (3,414 ) $ - $ 11,586 2021 Convertible promissory notes payable In default 15.40 % $ 0.1071 6,445 (1,099 ) 6,255 11,601 Convertible promissory notes payable, related parties In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan #2 February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts March 11, 2022 n/a n/a 1,500 (1,054 ) - 446 Total debt outstanding, including amounts in default 25,574 (5,567 ) 6,255 26,262 Less: current maturities, including notes in default (24,699 ) 5,567 (6,255 ) (25,387 ) Total long-term debt as of December 31, 2021 $ 875 $ - $ - $ 875 Senior secured promissory note payable, in default - In August 2020, the Company entered into a Note and Warrant Purchase and Security Agreement (the “NWPSA”) with NH Expansion Credit Fund Holdings LP, as noteholder and agent. The Company issued a $15 million Senior Secured Promissory Note Payable and a warrant exercisable into shares of the Company’s common stock (the “NH Expansion Warrant”) in exchange for cash to support operations, repay outstanding debt and close on the acquisition of the UltraMIST® assets from Celularity, among other transactions. In February 2022, the Company entered into the Second Amendment to Note and Warrant Purchase and Security Agreement (the “Second NWPSA”) for $3.0 million, for a total of $18.0 million outstanding, at an interest rate of 20.5% and maturity dates of September 30, 2025. Because the combined fair value of the applicable warrants and common stock issued as part of this note exceeded the face value of the note, the additional amount beyond the face value is recorded as a loss on issuance of $3.4 million. In June 2022, the Company entered into the Third Amendment to the Note and Warrant Purchase and Security Agreement (the “Third NWPSA”). The Third NWPSA provides for (i) the extension of the agent’s and holder’s forbearance of exercising its remedies arising from Existing Defaults (as defined in the NWPSA) to the earlier of (x) the occurrence of an Event of Default (as defined in the NWPSA) or (y) August 30, 2022, and (ii) the extension to file a registration statement with the Securities and Exchange Commission to register the resale of the Advisor Shares (as defined in the NWPSA) no later than August 30, 2022. Convertible Notes Payable and Convertible Notes Payable, Related Parties - On August 5, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), for our sale in a private placement (the “Private Placement”) of (i) Future Advance Convertible Promissory Notes (the “Notes”) in an aggregate principal amount of $16.2 million, consisting of $12.3 million in newly raised capital and $3.8 million in refinanced accrued expenses, bridge notes payable, convertible promissory notes, related parties, and fees, (ii) Common Stock Purchase Warrants (the “First Warrants”) to purchase an additional 404.8 million shares of common stock with an exercise price of $0.067 per share and (iii)Common Stock Purchase Warrants (the “Second Warrants”) to purchase an additional 404.8 million shares of common stock with an exercise price of $0.04 per share. The Notes will be convertible and the First and Second Warrants exercisable at such time as the Company’s authorized and unissued shares of common stock are at a number sufficient to permit the exercise or conversion of all outstanding securities exercisable for, or convertible into, common stock. The Company paid issuance costs totaling approximately $1.4 million. Pursuant to the Notes, the Company promised to pay in cash and/or in shares of common stock, at a conversion price of $0.04 (the “Conversion Price”), the principal amount and interest at a rate of 15% per annum on any outstanding principal. The Conversion Price of the Notes is subject to adjustment, including if the Company issues or sells shares of common stock for a price per share less than the Conversion Price of the Notes or if the Company lists its shares of common stock on The Nasdaq Capital Market and the average volume weighted average price of such common stock for the five May 2022 Advance on Future Receipts Financing – On May 19, 2022, the Company paid off the remaining balance of $400 thousand from the December 22, 2021, advance and received $545 thousand in cash proceeds related to its entry into a non-recourse agreement for the sale of $1.0 million of future receipts to GCF Resources LLC (“GCF”). In conjunction with the 24-week agreement, the Company is obligated to remit to GCF a minimum of $59 thousand of receipts each week for the twenty-four weeks. The Company began making the required minimum weekly payments May 23, 2022, and is obligated to continue through October 31, 2022. Because the combined fair value of the applicable warrants issued as part of this note exceeded the original payoff value of the note, the additional amount beyond the face value is recorded as a loss on extinguishment of $211 thousand in the statement of operations for the nine-months ended September 30, 2022. 2021 Convertible Promissory Notes Payable – Previously, the Company entered into a Securities Purchase Agreement (the “Leviston Purchase Agreement”), with Leviston Resources, LLC, an accredited investor (“Leviston”) for the sale by the Company in a private placement (the “Leviston Private Placement”) of (i) the Company’s future advance convertible promissory note in an aggregate principal amount of up to $3.4 million, later amended to $4.2 million (the “Leviston Note”) and (ii) a warrant to purchase up to an additional 16,666,667 shares of common stock of the Company (the “Leviston Warrants”). The Leviston Warrants had an exercise price of $0.18 per share and a four-year term. Advances on the Leviston Notes totaled $1.9 million and warrants to purchase 9.3 million shares were outstanding prior to the settlement discussed below. In addition, the Company issues notes to five institutional investors totaling approximately $0.5 million (the “Five Institutions’ Notes”), which were subject to substantially the same terms and conditions as the Leviston Purchase Agreement. Warrants to purchase 2.8 million shares of common stock with an exercise price of $0.18 per share were issued and outstanding prior to the settlement discussed below. Upon the closing of the Private Placement in August 2022, the Leviston Notes and Five Institutions’ Notes were paid and settled in full using proceeds from the Private Placement. The settlement payment included cash totaling $3.9 million, which included accrued interest and penalties, and the issuance of Company shares of common stock totaling 19.4 million shares. The lenders surrendered the warrants to the Company. The Company recognized a $0.9 million loss on extinguishment of debt for the three month-period ended September 30, 2022. SBA Loan #2 – In July 2022, the Company received confirmation that the loan forgiveness application had been approved, therefore, during the three-months ended September 30, 2022, the Company recognized a gain on loan extinguishment totaling $1.0 million. Embedded Conversion Option Liability T he fair value of Conversion Option liability assumptions for the periods ended below At / / At / / Conversion Price (1) $ 0.04 $ 0.11 Interest Rate (annual) (2) 3.93 % 0.18 % Volatility (annual) (3) 393.20 % 289.65 % Time to Maturity (Years) 0.85 0.50 (1) Based on the terms provided in the debt agreement to purchase common stock of the Company as of September 30, 2022, and December 31, 2021. (2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. (3) Based on the historical daily volatility of the Company as of December 31, 2021. Based on the historical weekly volatility of the Company with an applied discount rate of 7.5% as of September 30, 2022. The fair value for the Conversion Option liability was determined using the Black Scholes method as of September 30, 2022. As of September 30, 2022, the value of the underlying shares used in the Black Scholes model was $0.005 per share stock price. A binomial pricing model was used to determine the fair value of the Conversion Option as of December 31, 2021. As of December 31, 2021, the stock price used in the binomial pricing model was $0.17 per share. This conversion liability was settled with the 2021 Convertible Promissory Notes payable in August 2022. |
Common Stock Purchase Warrants
Common Stock Purchase Warrants | 9 Months Ended |
Sep. 30, 2022 | |
Common Stock Purchase Warrants [Abstract] | |
Common Stock Purchase Warrants | 8. Common Stock Purchase Warrants A summary of the warrant activity as of September is as follows (warrants in s): Weighted Weighted Average Average Remaining Exercise Price Contractual Life Warrants per share (years) Outstanding at December 204,883 $ 0.20 2.54 Exercised (27,946 ) 0.01 Issued 829,554 0.05 Outstanding at September 1,006,491 $ 0.08 5.00 On January 31, 2022, the Company issued 14 million shares of its common stock to LGH Investments LLC (“LGH”) upon the cashless exercise warrants exercisable for 15.0 million shares of common stock under the terms of the warrant agreement. After this cashless exercise, LGH owns warrants exercisable for 8.6 million shares of common stock. On February 28, 2022, the Company issued warrants exercisable for 16.1 million shares of common stock with an exercise price of $0.18 per share and an 8.6-year term as part of the Second NWPSA. On August 5, 2022, as part of the Private Placement, the Company issued First Warrants to purchase an additional 404.8 million shares of common stock with an exercise price of $0.067 per share and Second Warrants to purchase an additional 404.8 million shares of common stock with an exercise price of $0.04 per share. The exercise price of the Warrants is subject to adjustment, including if we issue or sell shares of common stock or share equivalents (as defined in the Warrants) for an effective consideration price less than the exercise price of the Warrants or if the Company lists its shares of common stock on The Nasdaq Capital Market and the average volume weighted average price of such common stock for the five |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Measurements [Abstract] | |
Fair Value Measurements | 9. Fair Value Measurements In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants and certain embedded conversion features associated with a convertible debt on a recurring basis to determine the fair value of the liability. The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2022, and December 31, 2021 (in thousands): Fair value measured at September 30, 2022 Quoted prices in Significant other Significant Fair value at active markets observable inputs unobservable inputs September 30, 2022 (Level 1) (Level 2) (Level 3) Warrant liability $ 1,196 $ - $ - $ 1,196 Embedded conversion option 1,922 - - 1,922 Total fair value $ 3,118 $ - $ - $ 3,118 Fair value measured at December 31, 2021 Quoted prices in Significant other Significant Fair value at active markets observable inputs unobservable inputs December 31, 2021 (Level 1) (Level 2) (Level 3) Warrant liability $ 9,614 $ - $ - $ 9,614 Embedded conversion option 6,255 - - 6,255 Total fair value $ 15,869 $ - $ - $ 15,869 There were no transfers between Level 1, 2 or 3 during the three and nine months ended September 30, 2022, and 2021. The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g. changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (dollars in thousands): Warrant Conversion Liability Feature Total Balance at December 31, 2021 $ 9,614 $ 6,255 $ 15,869 Issuance of Convertible Notes - 2,309 2,309 Cashless exercise (2,167 ) - (2,167 ) Settlement of Convertible Notes (963 ) (218 ) (1,181 ) Warrants issued 4,885 - 4,885 Change in fair value (10,173 ) (6,424 ) (16,597 ) Balance at September 30 2022 $ 1,196 $ 1,922 $ 3,118 A summary of the warrant liability activity for the nine months ended September 30, 2022, is as follows: Warrants Fair Value Fair Value Outstanding per Share (in thousands) Balance at December 31, 2021 62,617,188 $ 0.15 $ 9,614 Warrants exercised (27,037,038 ) 0.12 (3,130 ) Warrants issued 829,553,984 0.01 4,885 Gain on remeasurement of warrant liability - (10,173 ) Balance at September 30 2022 865,134,134 $ 0.00 $ 1,196 Significant inputs related to the Company’s liability classified warrants are listed below. September 30, December 31, New Issuance 2022 2021 at Issue Date Weighted average remaining life in years 4.89 4.67 5.00 Weighted average volatility 87 % 116 % 85 % Weighted average risk free interest rate 4.0 % 1.2 % 2.9 % Expected dividend yield 0.00 % 0.00 % 0.00 % |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies [Abstract] | |
Commitments and Contingencies | 10. Commitments and Contingencies In the ordinary course of business, the Company from time to time becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Companies expenses legal fees in the period in which they are occurred. Supplier disputes |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | 11. Subsequent Events On November 14, 2022, the Company issued (i) Notes in an aggregate principal amount of approximately $2 million, (ii) First Warrants to purchase approximately 45 million shares of common stock with an exercise price of $0.067 per share and (iii) Second Warrants to purchase approximately 45 million shares of common stock with an exercise price of $0.04 per share, in each case pursuant to the Purchase Agreement. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Summary of Significant Accounting Policies [Abstract] | |
Estimates | Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and the estimated fair value of financial instruments, including warrants and embedded conversion options. |
Loss per Share (Tables)
Loss per Share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Loss per Share [Abstract] | |
Weighted Average Shares Outstanding | Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows (shares in thousands): Three Months Ended Nine Months Ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Weighted average shares outstanding Common shares 540,584 481,620 519,127 481,620 Common shares issuable assuming exercise of nominally priced warrants 20,486 36,691 23,358 36,751 Weighted average shares outstanding 561,070 518,311 542,485 518,370 |
Anti-dilutive Equity Securities | Anti-dilutive equity securities consist of the following for the nine months ended September 30, 2022, and 2021, respectively (in thousands): Nine Months Ended September 30, 2022 September 30, 2021 Common stock options 21,246 31,760 Common stock purchase warrants 984,799 159,858 Convertible notes payable 483,588 98,675 1,489,633 290,293 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accrued Expenses [Abstract] | |
Accrued Expenses | Accrued expenses consist of the following on September and December (in s): 2022 2021 Registration penalties $ 1,593 $ 1,950 License fees 893 893 Board of director’s fees 663 507 Other 951 1,044 $ 4,100 $ 4,394 |
Concentration of Credit Risk _2
Concentration of Credit Risk and Limited Suppliers (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Concentration of Credit Risk and Limited Suppliers [Abstract] | |
Concentration of Credit Risk and Limited Suppliers | Major customers are defined as customers whose accounts receivable, or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable from major customers of the Company for the periods indicated were as follows: September 30, 2022 December 31, 2021 Accounts Receivable: Customer A 12 % 24 % Customer B 10 % 16 % The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The of purchases from major vendors of the Company that exceeded of total purchases for the and nine months ended September and were as follows: Three Months Ended Nine Months Ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Purchases: Vendor A 18 % 52 % 18 % 46 % Vendor B n/a n/a n/a 15 % |
Notes Payable (Tables)
Notes Payable (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Payable [Abstract] | |
Outstanding Notes Payable | The following two tables summarize outstanding notes payable as of September 30, 2022, and December 31, 2021 (dollars in thousands): As of 09/30/2022 (dollars in thousands) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable In default 20.5 % n/a $ 18,000 $ (5,227 ) $ - $ 12,773 2021 Convertible promissory notes payable In default 17.0 % $ 0.0538 4,000 - - 4,000 Convertible promissory notes payable, related parties In default 14.0 % $ 0.10 1,373 - - 1,373 Convertible notes payable August 5, 2023 15.0 % $ 0.04 10,849 (2,966 ) 1,291 9,174 Convertible notes payable, related parties August 5, 2023 15.0 % $ 0.04 5,305 (1,451 ) 631 4,485 Advances on future cash receipts In default n/a n/a 296 (102 ) - 194 Total short-term debt as of September 30, 2022, including notes in default $ 39,823 $ (9,746 ) $ 1,922 $ 31,999 As of 12/31/2021 (dollars in thousands) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable In default 20.25 % n/a $ 15,000 $ (3,414 ) $ - $ 11,586 2021 Convertible promissory notes payable In default 15.40 % $ 0.1071 6,445 (1,099 ) 6,255 11,601 Convertible promissory notes payable, related parties In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan #2 February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts March 11, 2022 n/a n/a 1,500 (1,054 ) - 446 Total debt outstanding, including amounts in default 25,574 (5,567 ) 6,255 26,262 Less: current maturities, including notes in default (24,699 ) 5,567 (6,255 ) (25,387 ) Total long-term debt as of December 31, 2021 $ 875 $ - $ - $ 875 |
Fair Value of Conversion Option liability | T he fair value of Conversion Option liability assumptions for the periods ended below At / / At / / Conversion Price (1) $ 0.04 $ 0.11 Interest Rate (annual) (2) 3.93 % 0.18 % Volatility (annual) (3) 393.20 % 289.65 % Time to Maturity (Years) 0.85 0.50 (1) Based on the terms provided in the debt agreement to purchase common stock of the Company as of September 30, 2022, and December 31, 2021. (2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. (3) Based on the historical daily volatility of the Company as of December 31, 2021. Based on the historical weekly volatility of the Company with an applied discount rate of 7.5% as of September 30, 2022. |
Common Stock Purchase Warrants
Common Stock Purchase Warrants (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Common Stock Purchase Warrants [Abstract] | |
Warrant Activity | A summary of the warrant activity as of September is as follows (warrants in s): Weighted Weighted Average Average Remaining Exercise Price Contractual Life Warrants per share (years) Outstanding at December 204,883 $ 0.20 2.54 Exercised (27,946 ) 0.01 Issued 829,554 0.05 Outstanding at September 1,006,491 $ 0.08 5.00 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Measurements [Abstract] | |
Liabilities Measured at Fair Value on Recurring Basis | The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2022, and December 31, 2021 (in thousands): Fair value measured at September 30, 2022 Quoted prices in Significant other Significant Fair value at active markets observable inputs unobservable inputs September 30, 2022 (Level 1) (Level 2) (Level 3) Warrant liability $ 1,196 $ - $ - $ 1,196 Embedded conversion option 1,922 - - 1,922 Total fair value $ 3,118 $ - $ - $ 3,118 Fair value measured at December 31, 2021 Quoted prices in Significant other Significant Fair value at active markets observable inputs unobservable inputs December 31, 2021 (Level 1) (Level 2) (Level 3) Warrant liability $ 9,614 $ - $ - $ 9,614 Embedded conversion option 6,255 - - 6,255 Total fair value $ 15,869 $ - $ - $ 15,869 |
Warrants Outstanding and Fair Values | The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g. changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (dollars in thousands): Warrant Conversion Liability Feature Total Balance at December 31, 2021 $ 9,614 $ 6,255 $ 15,869 Issuance of Convertible Notes - 2,309 2,309 Cashless exercise (2,167 ) - (2,167 ) Settlement of Convertible Notes (963 ) (218 ) (1,181 ) Warrants issued 4,885 - 4,885 Change in fair value (10,173 ) (6,424 ) (16,597 ) Balance at September 30 2022 $ 1,196 $ 1,922 $ 3,118 A summary of the warrant liability activity for the nine months ended September 30, 2022, is as follows: Warrants Fair Value Fair Value Outstanding per Share (in thousands) Balance at December 31, 2021 62,617,188 $ 0.15 $ 9,614 Warrants exercised (27,037,038 ) 0.12 (3,130 ) Warrants issued 829,553,984 0.01 4,885 Gain on remeasurement of warrant liability - (10,173 ) Balance at September 30 2022 865,134,134 $ 0.00 $ 1,196 |
Fair Value of Warrant Liabilities Using Black-Scholes Model | Significant inputs related to the Company’s liability classified warrants are listed below. September 30, December 31, New Issuance 2022 2021 at Issue Date Weighted average remaining life in years 4.89 4.67 5.00 Weighted average volatility 87 % 116 % 85 % Weighted average risk free interest rate 4.0 % 1.2 % 2.9 % Expected dividend yield 0.00 % 0.00 % 0.00 % |
Nature of the Business and Ba_2
Nature of the Business and Basis of Presentation (Details) | Aug. 06, 2020 Product |
Nature of the Business and Basis of Presentation [Abstract] | |
Number of energy transfer technology products | 2 |
Number of human tissues biological products | 2 |
Loss per Share, Weighted Averag
Loss per Share, Weighted Average Shares Outstanding (Details) - $ / shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Weighted Average Shares Outstanding [Abstract] | ||||
Weighted average shares outstanding basic (in shares) | 561,069,625 | 518,310,781 | 542,484,779 | 518,370,156 |
Warrant exercise price (in dollars per share) | $ 0.01 | |||
Common Shares [Member] | ||||
Weighted Average Shares Outstanding [Abstract] | ||||
Weighted average shares outstanding basic (in shares) | 540,584,000 | 481,620,000 | 519,127,000 | 481,620,000 |
Common Shares Issuable Assuming Exercise of Nominally Priced Warrants [Member] | ||||
Weighted Average Shares Outstanding [Abstract] | ||||
Weighted average shares outstanding basic (in shares) | 20,486,000 | 36,691,000 | 23,358,000 | 36,751,000 |
Loss per Share, Anti Dilutive E
Loss per Share, Anti Dilutive Equity Securities (Details) - shares shares in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Anti-dilutive Securities [Abstract] | ||
Anti-dilutive equity securities (in shares) | 1,489,633 | 290,293 |
Common Stock Options [Member] | ||
Anti-dilutive Securities [Abstract] | ||
Anti-dilutive equity securities (in shares) | 21,246 | 31,760 |
Common Stock Purchase Warrants [Member] | ||
Anti-dilutive Securities [Abstract] | ||
Anti-dilutive equity securities (in shares) | 984,799 | 159,858 |
Convertible Notes Payable [Member] | ||
Anti-dilutive Securities [Abstract] | ||
Anti-dilutive equity securities (in shares) | 483,588 | 98,675 |
Accrued Expenses (Details)
Accrued Expenses (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Dec. 31, 2021 | |
Accrued Expense [Abstract] | ||
Registration penalties | $ 1,593 | $ 1,950 |
License fees | 893 | 893 |
Board of director's fees | 663 | 507 |
Other | 951 | 1,044 |
Total accrued expenses | 4,100 | $ 4,394 |
Warranty reserve accrual | $ 0 |
Concentration of Credit Risk _3
Concentration of Credit Risk and Limited Suppliers (Details) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer A [Member] | |||||
Concentration of Credit Risk and Limited Suppliers [Abstract] | |||||
Concentration risk, percentage | 12% | 24% | |||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer B [Member] | |||||
Concentration of Credit Risk and Limited Suppliers [Abstract] | |||||
Concentration risk, percentage | 10% | 16% | |||
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor A [Member] | |||||
Concentration of Credit Risk and Limited Suppliers [Abstract] | |||||
Concentration risk, percentage | 18% | 52% | 18% | 46% | |
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor B [Member] | |||||
Concentration of Credit Risk and Limited Suppliers [Abstract] | |||||
Concentration risk, percentage | 15% |
Notes Payable, Outstanding Note
Notes Payable, Outstanding Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Senior Secured Promissory Notes Payable [Abstract] | ||
Short-term debt | $ 31,999 | |
Long-term debt gross | $ 25,574 | |
Long-term debt gross, current | 39,823 | (24,699) |
Long-term debt gross, noncurrent | 875 | |
Remaining debt discount | (9,746) | (5,567) |
Senior secured promissory note payable, in default | 12,773 | 11,586 |
Remaining debt discount, current | 5,567 | |
Remaining debt discount, noncurrent | 0 | |
Remaining embedded conversion option | 6,255 | |
Remaining embedded conversion option, current | 1,922 | (6,255) |
Remaining embedded conversion option, noncurrent | 0 | |
Convertible promissory note payable, in default | 9,174 | 0 |
Advances on future cash receipts | $ 194 | 446 |
Debt, Long-term and Short-term, Combined Amount [Abstract] | ||
Long-term debt net | 26,262 | |
Long-term debt net, current | (25,387) | |
Long-term debt net, noncurrent | $ 875 | |
SBA Loan #2 [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | Feb. 20, 2026 | |
Interest rate | 1% | |
Principal amount | $ 1,033 | |
Remaining debt discount | 0 | |
Remaining embedded conversion option | 0 | |
SBA loans | $ 1,033 | |
Advances on Future Cash Receipts [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | In default | |
Maturity date | Mar. 11, 2022 | |
Principal amount | $ 296 | $ 1,500 |
Remaining debt discount | (102) | (1,054) |
Remaining embedded conversion option | 0 | 0 |
Advances on future cash receipts | $ 194 | $ 446 |
Senior Secured Promissory Note [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | In default | In default |
Interest rate | 20.50% | 20.25% |
Principal amount | $ 18,000 | $ 15,000 |
Remaining debt discount | (5,227) | (3,414) |
Senior secured promissory note payable, in default | 12,773 | 11,586 |
Remaining embedded conversion option | $ 0 | $ 0 |
2021 Convertible Promissory Notes Payable [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | In default | In default |
Interest rate | 17% | 15.40% |
Conversion price (in dollars per share) | $ 0.0538 | $ 0.1071 |
Principal amount | $ 4,000 | $ 6,445 |
Remaining debt discount | 0 | (1,099) |
Remaining embedded conversion option | 0 | 6,255 |
Convertible promissory note payable, in default | $ 4,000 | $ 11,601 |
Convertible Promissory Notes Payable, Related Parties [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | In default | In default |
Interest rate | 14% | 14% |
Conversion price (in dollars per share) | $ 0.1 | $ 0.1 |
Principal amount | $ 1,373 | $ 1,596 |
Remaining debt discount | 0 | 0 |
Remaining embedded conversion option | 0 | 0 |
Convertible promissory notes payable, related parties, in default | $ 1,373 | $ 1,596 |
Convertible Notes Payable [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | Aug. 05, 2023 | |
Interest rate | 15% | |
Conversion price (in dollars per share) | $ 0.04 | |
Principal amount | $ 10,849 | |
Remaining debt discount | (2,966) | |
Remaining embedded conversion option | 1,291 | |
Convertible promissory notes payable, related parties, in default | $ 9,174 | |
Convertible Notes Payable, Related Parties [Member] | ||
Senior Secured Promissory Notes Payable [Abstract] | ||
Maturity date | Aug. 05, 2023 | |
Interest rate | 15% | |
Conversion price (in dollars per share) | $ 0.04 | |
Principal amount | $ 5,305 | |
Remaining debt discount | (1,451) | |
Remaining embedded conversion option | 631 | |
Convertible promissory notes payable, related parties, in default | $ 4,485 |
Notes Payable, Senior Secured P
Notes Payable, Senior Secured Promissory Note Payable, in Default (Details) - Senior Secured Promissory Note [Member] - USD ($) $ in Thousands | 9 Months Ended | |||
Sep. 30, 2022 | Feb. 28, 2022 | Dec. 31, 2021 | Aug. 31, 2020 | |
Senior Secured Promissory Notes Payable [Abstract] | ||||
Principal amount | $ 18,000 | $ 15,000 | ||
Interest rate | 20.50% | 20.25% | ||
NH Expansion Credit Fund Holdings LP [Member] | ||||
Senior Secured Promissory Notes Payable [Abstract] | ||||
Principal amount | $ 15,000 | |||
NH Expansion Credit Fund Holdings LP [Member] | Second Amendment to Note and Warrant Purchase and Security Agreement [Member] | ||||
Senior Secured Promissory Notes Payable [Abstract] | ||||
Principal amount | $ 18,000 | $ 3,000 | ||
Interest rate | 20.50% | |||
Maturity date | Sep. 30, 2025 | |||
Loss on issuance | $ 3,400 |
Notes Payable, Convertible Note
Notes Payable, Convertible Notes Payable and Convertible Notes Payable, Related Parties (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | Aug. 05, 2022 | Sep. 30, 2022 | Dec. 31, 2021 |
Convertible Notes Payable and Convertible Notes Payable, Related Parties [Abstract] | |||
Warrant exercise price (in dollars per share) | $ 0.08 | $ 0.2 | |
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] | |||
Convertible Notes Payable and Convertible Notes Payable, Related Parties [Abstract] | |||
Aggregate principal amount | $ 16.2 | ||
Newly raised capital | 12.3 | ||
Accrued expenses and fees refinanced | 3.8 | ||
Payment of debt issuance costs | $ 1.4 | ||
Interest rate | 15% | ||
Conversion price (in dollars per share) | $ 0.04 | ||
Number of trading days | 5 days | ||
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] | Maximum [Member] | |||
Convertible Notes Payable and Convertible Notes Payable, Related Parties [Abstract] | |||
Conversion price (in dollars per share) | $ 0.01 | ||
Share price (in dollars per share) | $ 0.04 | ||
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] | First Warrant [Member] | |||
Convertible Notes Payable and Convertible Notes Payable, Related Parties [Abstract] | |||
Warrants to purchase common stock (in shares) | 404.8 | ||
Warrant exercise price (in dollars per share) | $ 0.067 | ||
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] | Second Warrant [Member] | |||
Convertible Notes Payable and Convertible Notes Payable, Related Parties [Abstract] | |||
Warrants to purchase common stock (in shares) | 404.8 | ||
Warrant exercise price (in dollars per share) | $ 0.04 |
Notes Payable, May 2022 Advance
Notes Payable, May 2022 Advance on Future Receipts Financing (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
May 19, 2022 USD ($) wk | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | |
May 2022 Advance on Future Receipts Financing [Abstract] | |||||
Loss on extinguishment of debt | $ (86) | $ 460 | $ (297) | $ 460 | |
May 2022 Advances on Future Receipts Financing [Member] | |||||
May 2022 Advance on Future Receipts Financing [Abstract] | |||||
Balance paid | $ 400 | ||||
Cash proceeds | 545 | ||||
Sale of future receipts | $ 1,000 | ||||
Non-recourse agreement term | wk | 24 | ||||
Minimum amount of receipts, payment | $ 59 | ||||
Receipts of remaining term | wk | 24 | ||||
Loss on extinguishment of debt | $ (211) |
Notes Payable, 2021 Convertible
Notes Payable, 2021 Convertible Promissory Notes Payable (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||
Sep. 03, 2021 USD ($) Investors $ / shares shares | Apr. 20, 2021 USD ($) $ / shares shares | Aug. 31, 2022 USD ($) shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 $ / shares shares | May 14, 2021 USD ($) | |
2021 Convertible Promissory Notes Payable [Abstract] | |||||||||
Warrant exercise price (in dollars per share) | $ / shares | $ 0.08 | $ 0.08 | $ 0.2 | ||||||
Proceeds from, promissory note disbursement | $ 2,940 | $ 940 | |||||||
Warrants to purchase shares outstanding (in shares) | shares | 1,006,491 | 1,006,491 | 204,883 | ||||||
Cash payment | $ 2,981 | 237 | |||||||
Loss on extinguishment of debt | $ (86) | $ 460 | $ (297) | $ 460 | |||||
April 2021 Securities Purchase Agreement and Warrants [Member] | |||||||||
2021 Convertible Promissory Notes Payable [Abstract] | |||||||||
Aggregate principal amount | $ 4,200 | ||||||||
Warrants to purchase additional common stock (in shares) | shares | 16,666,667 | ||||||||
Warrant exercise price (in dollars per share) | $ / shares | $ 0.18 | ||||||||
Warrants term period | 4 years | ||||||||
Proceeds from, promissory note disbursement | $ 1,900 | ||||||||
Warrants to purchase shares outstanding (in shares) | shares | 9,300,000 | ||||||||
April 2021 Securities Purchase Agreement and Warrants [Member] | Maximum [Member] | |||||||||
2021 Convertible Promissory Notes Payable [Abstract] | |||||||||
Aggregate principal amount | $ 3,400 | ||||||||
April 2021 Securities Purchase Agreement and Warrants [Member] | Five Institutions' Notes [Member] | |||||||||
2021 Convertible Promissory Notes Payable [Abstract] | |||||||||
Aggregate principal amount | $ 500 | ||||||||
Warrants to purchase additional common stock (in shares) | shares | 2,800,000 | ||||||||
Warrant exercise price (in dollars per share) | $ / shares | $ 0.18 | ||||||||
Number of institutional investors | Investors | 5 | ||||||||
Leviston Resources LLC [Member] | |||||||||
2021 Convertible Promissory Notes Payable [Abstract] | |||||||||
Cash payment | $ 3,900 | ||||||||
Shares issued (in shares) | shares | 19,400,000 | ||||||||
Loss on extinguishment of debt | $ (900) |
Notes Payable, SBA Loan #2 (Det
Notes Payable, SBA Loan #2 (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
SBA Loans [Abstract] | ||||
Gain on extinguishment of debt | $ (86) | $ 460 | $ (297) | $ 460 |
SBA Loan #2 [Member] | ||||
SBA Loans [Abstract] | ||||
Gain on extinguishment of debt | $ 1,000 |
Notes Payable, Embedded Convers
Notes Payable, Embedded Conversion Option Liability (Details) - Binomial Pricing Model [Member] | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2022 $ / shares | Dec. 31, 2021 $ / shares | ||
Measurement Input, Conversion Price [Member] | |||
Embedded Conversion Option Liability [Abstract] | |||
Conversion Price (in dollars per share) | [1] | $ 0.04 | $ 0.11 |
Measurement Input, Interest Rate (annual) [Member] | |||
Embedded Conversion Option Liability [Abstract] | |||
Measurement input | [2] | 0.0393 | 0.0018 |
Measurement Input, Volatility (annual) [Member] | |||
Embedded Conversion Option Liability [Abstract] | |||
Measurement input | [3] | 3.932 | 2.8965 |
Measurement Input, Time to Maturity (Years) [Member] | |||
Embedded Conversion Option Liability [Abstract] | |||
Time to Maturity (Years) | 10 months 6 days | 6 months | |
Measurement Input, Applied Discount Rate [Member] | |||
Embedded Conversion Option Liability [Abstract] | |||
Measurement input | 0.075 | ||
Measurement Input, Share Price [Member] | |||
Embedded Conversion Option Liability [Abstract] | |||
Measurement input | 0.005 | 0.17 | |
[1]Based on the terms provided in the debt agreement to purchase common stock of the Company as of September 30, 2022, and December 31, 2021.[2] Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve. |
Common Stock Purchase Warrant_2
Common Stock Purchase Warrants (Details) - $ / shares | 9 Months Ended | 12 Months Ended | |||
Aug. 05, 2022 | Feb. 28, 2022 | Jan. 31, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | |
Warrants [Abstract] | |||||
Outstanding, beginning (in shares) | 204,883 | ||||
Exercised (in shares) | (27,946) | ||||
Issued (in shares) | 829,554 | ||||
Outstanding, ending (in shares) | 1,006,491 | 204,883 | |||
Weighted Average Exercise Price per share [Abstract] | |||||
Outstanding, beginning (in dollars per share) | $ 0.2 | ||||
Exercised (in dollars per share) | 0.01 | ||||
Issued (in dollars per share) | 0.05 | ||||
Outstanding, ending (in dollars per share) | $ 0.08 | $ 0.2 | |||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Weighted Average Remaining Contractual Life (years) | 5 years | 2 years 6 months 14 days | |||
Issued (in shares) | 829,553,984 | ||||
Warrant exercise price (in dollars per share) | $ 0.08 | $ 0.2 | |||
Black Scholes Model [Member] | |||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Share price (in dollars per share) | $ 0.005 | ||||
NH Expansion Fund [Member] | |||||
Weighted Average Exercise Price per share [Abstract] | |||||
Outstanding, ending (in dollars per share) | $ 0.18 | ||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Issued (in shares) | 16,100,000 | ||||
Warrants term period | 8 years 7 months 6 days | ||||
Warrant exercise price (in dollars per share) | $ 0.18 | ||||
Private Placement [Member] | |||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Warrants term period | 5 years | ||||
Number of trading days | 5 days | ||||
Private Placement [Member] | Maximum [Member] | |||||
Weighted Average Exercise Price per share [Abstract] | |||||
Outstanding, ending (in dollars per share) | $ 0.01 | ||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Warrant exercise price (in dollars per share) | 0.01 | ||||
Share price (in dollars per share) | 0.04 | ||||
LGH Warrants [Member] | |||||
Warrants [Abstract] | |||||
Exercised (in shares) | (15,000,000) | ||||
Outstanding, ending (in shares) | 8,600,000 | ||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Issued (in shares) | 14,000,000 | ||||
First Warrant [Member] | Private Placement [Member] | |||||
Weighted Average Exercise Price per share [Abstract] | |||||
Outstanding, ending (in dollars per share) | $ 0.067 | ||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Warrants to purchase common stock (in shares) | 404,800,000 | ||||
Warrant exercise price (in dollars per share) | $ 0.067 | ||||
Second Warrant [Member] | Private Placement [Member] | |||||
Weighted Average Exercise Price per share [Abstract] | |||||
Outstanding, ending (in dollars per share) | $ 0.04 | ||||
Weighted Average Remaining Contractual Life (Years) [Abstract] | |||||
Warrants to purchase common stock (in shares) | 404,800,000 | ||||
Warrant exercise price (in dollars per share) | $ 0.04 |
Fair Value Measurements, Liabil
Fair Value Measurements, Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract] | |||||
Transfer to level 3 | $ 0 | $ 0 | $ 0 | $ 0 | |
Transfer from level 3 | 0 | $ 0 | 0 | $ 0 | |
Recurring [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 3,118 | 3,118 | $ 15,869 | ||
Recurring [Member] | Warrant Liability [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 1,196 | 1,196 | 9,614 | ||
Recurring [Member] | Embedded Conversion Option [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 1,922 | 1,922 | 6,255 | ||
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 0 | 0 | 0 | ||
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Warrant Liability [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 0 | 0 | 0 | ||
Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Embedded Conversion Option [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 0 | 0 | 0 | ||
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 0 | 0 | 0 | ||
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Warrant Liability [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 0 | 0 | 0 | ||
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Embedded Conversion Option [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 0 | 0 | 0 | ||
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 3,118 | 3,118 | 15,869 | ||
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | Warrant Liability [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | 1,196 | 1,196 | 9,614 | ||
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | Embedded Conversion Option [Member] | |||||
Financial Liabilities Fair Value Disclosure [Abstract] | |||||
Liabilities at fair value | $ 1,922 | $ 1,922 | $ 6,255 |
Fair Value Measurements, Warran
Fair Value Measurements, Warrants Fair Value, Outstanding and Valuation Model (Details) $ / shares in Units, $ in Thousands | 9 Months Ended | ||
Sep. 30, 2022 USD ($) $ / shares shares | Feb. 28, 2022 | Dec. 31, 2021 USD ($) $ / shares shares | |
Fair Value, Warrant Liability [Abstract] | |||
Warrant Liability, Fair Value | $ 1,196 | $ 9,614 | |
Warrants issued | 4,885 | ||
Gain on remeasurement of warrant liability | $ (10,173) | ||
Warrant Outstanding and Fair Value [Abstract] | |||
Warrants outstanding (in shares) | shares | 865,134,134 | 62,617,188 | |
Warrants issued (in shares) | shares | 829,553,984 | ||
Warrants issued (in dollars per share) | $ / shares | $ 0.01 | ||
Gain on remeasurement of warrant liability (in shares) | shares | 0 | ||
Fair value per share (in dollars per share) | $ / shares | $ 0 | $ 0.15 | |
Measurement Input, Weighted Average Expected Life in Years [Member] | |||
Black Scholes Option Pricing Model [Abstract] | |||
Weighted average expected life in years (Years) | 4 years 10 months 20 days | 5 years | 4 years 8 months 1 day |
Measurement Input, Weighted Average Volatility (annual) [Member] | |||
Black Scholes Option Pricing Model [Abstract] | |||
Warrants measurement input | 0.87 | 0.85 | 1.16 |
Measurement Input, Weighted Average Risk Free Interest Rate [Member] | |||
Black Scholes Option Pricing Model [Abstract] | |||
Warrants measurement input | 0.04 | 0.029 | 0.012 |
Measurement Input, Expected Dividend Yield [Member] | |||
Black Scholes Option Pricing Model [Abstract] | |||
Warrants measurement input | 0 | 0 | 0 |
Warrant Classified [Member] | |||
Fair Value, Warrant Liability [Abstract] | |||
Warrants exercised | $ (3,130) | ||
Warrant Outstanding and Fair Value [Abstract] | |||
Warrants exercised (in shares) | shares | (27,037,038) | ||
Warrants exercised (in dollars per share) | $ / shares | $ 0.12 | ||
Level 3 [Member] | |||
Fair Value, Warrant Liability [Abstract] | |||
Warrant Liability, Fair Value | $ 3,118 | $ 15,869 | |
Issuance of Convertible Notes | 2,309 | ||
Cashless exercise | (2,167) | ||
Settlement of Convertible Notes | (1,181) | ||
Warrants issued | 4,885 | ||
Gain on remeasurement of warrant liability | (16,597) | ||
Level 3 [Member] | Warrant Liability [Member] | |||
Fair Value, Warrant Liability [Abstract] | |||
Warrant Liability, Fair Value | 1,196 | 9,614 | |
Issuance of Convertible Notes | 0 | ||
Cashless exercise | (2,167) | ||
Settlement of Convertible Notes | (963) | ||
Warrants issued | 4,885 | ||
Gain on remeasurement of warrant liability | (10,173) | ||
Level 3 [Member] | Conversion Feature [Member] | |||
Fair Value, Warrant Liability [Abstract] | |||
Warrant Liability, Fair Value | 1,922 | $ 6,255 | |
Issuance of Convertible Notes | 2,309 | ||
Cashless exercise | 0 | ||
Settlement of Convertible Notes | (218) | ||
Warrants issued | 0 | ||
Gain on remeasurement of warrant liability | $ (6,424) |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | Nov. 14, 2022 | Sep. 30, 2022 | Dec. 31, 2021 |
Subsequent Event [Abstract] | |||
Warrant exercise price (in dollars per share) | $ 0.08 | $ 0.2 | |
Subsequent Event [Member] | |||
Subsequent Event [Abstract] | |||
Aggregate principal amount | $ 2 | ||
First Warrant [Member] | Subsequent Event [Member] | |||
Subsequent Event [Abstract] | |||
Warrants to purchase common stock (in shares) | 45 | ||
Warrant exercise price (in dollars per share) | $ 0.067 | ||
Second Warrant [Member] | Subsequent Event [Member] | |||
Subsequent Event [Abstract] | |||
Warrants to purchase common stock (in shares) | 45 | ||
Warrant exercise price (in dollars per share) | $ 0.04 |